摘要
光动力疗法(PDT)是一种独特的消除各种实体肿瘤如前列腺、肺、膀胱和脑肿瘤的特异性治疗。PDT有三种情况:(i)感光剂(PS)的管理,(ii)PS由可见光或近红外光的光激发,(iii)分子氧。光激发后,PS产生肿瘤破坏性的活性氧,其中最主要的就是单线态氧(1O2)。之前的研究表明,内源性一氧化氮(NO)在多种小鼠肿瘤模型中能减弱PDT的效果。例如,在用5 -氨基乙酰丙酸(ALA)诱导的原卟啉IX致敏后用可见光照射,乳腺癌COH-BR1和前列腺癌PC3细胞一氧化氮合酶(iNOS)表现出快速和长期的上调。iNOS抑制剂和NO清除剂的使用表明NO对细胞抵抗和细胞凋亡具有关键作用。与对照组相比,此外 ALA/light存活细胞增殖,迁移,入侵更迅速。NO具有增强存活细胞攻击性的作用。最近研究表明,诱导的NO在PDT靶向PC3细胞也可以转移和增加非靶向细胞的侵袭性。PDT中NO负面的、潜在的促肿瘤副作用可以通过使用iNOS抑制剂作为辅佐药物来避免。本文对NO所引起的PDT拮抗作用的每一方面都进行了讨论。
关键词: 一氧化氮,诱导型一氧化氮合酶,肿瘤,光动力疗法,细胞凋亡,细胞迁移/侵袭,旁观效应。
Current Medicinal Chemistry
Title:Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy
Volume: 23 Issue: 24
Author(s): Albert W. Girotti, Jonathan M. Fahey, Witold Korytowski
Affiliation:
关键词: 一氧化氮,诱导型一氧化氮合酶,肿瘤,光动力疗法,细胞凋亡,细胞迁移/侵袭,旁观效应。
摘要: Photodynamic therapy (PDT) is a unique site-specific treatment for eradicating a variety of solid tumors, including prostate, lung, bladder, and brain tumors. PDT is a three-component modality involving (i) administration of a photosensitizing agent (PS), (ii) PS photoexcitation by visible or near-infrared light, and (iii) molecular oxygen. Upon photoexcitation, PS gives rise to tumor-damaging reactive oxygen species, most prominently singlet oxygen (1O2). Previous studies revealed that endogenous nitric oxide (NO) in various mouse tumor models significantly reduced PDT effectiveness. Recent studies in the authors’ laboratory indicated that NO produced by photostressed tumor cells per se can elicit anti-PDT effects. For example, breast cancer COH-BR1 and prostate cancer PC3 cells exhibited a rapid and prolonged upregulation of inducible nitric oxide synthase (iNOS) after sensitization with 5- aminolevulinic acid (ALA)-induced protoporphyrin-IX, followed by broad-band visible irradiation. Use of iNOS inhibitors and NO scavengers demonstrated that iNOS/NO played a key role in cell resistance to apoptotic photokilling. Moreover, cells surviving an ALA/light challenge proliferated, migrated, and invaded more rapidly than controls, again in iNOS/NOdependent fashion. Thus, NO was found to play a crucial role in various manifestations of enhanced aggressiveness exhibited by remaining live cells. Recent work has revealed that induced NO in PDT-targeted PC3 cells can also translocate and increase aggressiveness of non-targeted bystander cells. These negative and potentially tumor-promoting side effects of NO in PDT may be averted through use of iNOS inhibitors as adjuvants. Each of the above aspects of PDT antagonism by NO will be discussed in this review.
Export Options
About this article
Cite this article as:
Albert W. Girotti, Jonathan M. Fahey, Witold Korytowski , Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy, Current Medicinal Chemistry 2016; 23 (24) . https://dx.doi.org/10.2174/0929867323666160812145641
DOI https://dx.doi.org/10.2174/0929867323666160812145641 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design In vivo Near-infrared Fluorescence Tumor Imaging Using DiR-loaded Nanocarriers
Current Drug Delivery MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Molecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 EnzymesMolecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 Enzymes
Current Drug Metabolism Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
Current Cancer Drug Targets Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis Snake Venom L-Amino Acid Oxidases: Some Consideration About their Functional Characterization
Protein & Peptide Letters Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology